Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sanofi Pasteur H1N1 Vaccine Safety and Immunogenicity in Adults and Elderly
NCT00943631Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Aug 2009
- Primary completion
- Mar 2010
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CSL H1N1 Pandemic Influenza Vaccine in influenza, sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Vaccine-associated Serious Adverse Events and Solicited Local Reactions After the First Vaccination. Started Aug 2009; status: completed.
02
Drugs
CSL H1N1 Pandemic Influenza Vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00943631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00943631.